MUNICH, Germany, April 11, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health ("HMNC" or the "company"), a global precision psychiatry biopharma company, pioneering the development of personalized therapies powered by its nascent AI platform and predictive companion diagnostics suite, leading to far shorter treatment durations and higher remission rates, announced today that it will present at the following upcoming investor conferences in April 2022.
21st Annual Needham Virtual Healthcare Conference
Date: April 12, 2022
Time: 8:00am ET
Webcast:https://wsw.com/webcast/needham117/hmncbh/2587632
Benzinga Psychedelics Capital Conference
Date: April 19, 2022
Time: 1:50pm ET
Registration: https://www.benzinga.com/events/psychedelics/
Webcast: https://www.benzinga.com/events/psychedelics/livestream/
RHK NobleCon18:
Date: April 21, 2022
Time: 12:30pm ET
Registration: https://www.nobleconference.com/eighteenregister
Webcast:https://noble.mediasite.com/Mediasite/Play/acf2c43fdb2a4bec8adf0e392675e26c1d
To schedule a one-on-one meeting with HMNC Brain Health's management team, please contact KCSA Strategic Communications at hmncbrain@kcsa.com.
About HMNC Brain Health
HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company, pioneering the development of personalized therapies powered by its nascent AI platform and predictive companion diagnostics suite, leading to far shorter treatment durations and higher remission rates. The company develops a unique pipeline for targeting both Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). The company has operations in both the U.S. and Germany and is backed by a renowned global VC, several family offices, and a strategic healthcare investor. HMNC Brain Health now enters the next stage of its development with a large-scale licensing and fundraising agenda.
Media Contacts
Alexander Schmidt
Anne Donohoe
Investor Contact/ sbashford@kcsa.com
